Pharmaceuticals
Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis
SHANGHAI, May 15, 2023 /PRNewswire/ -- Rona Therapeutics, Inc ("Rona") and Keymed Biosciences ("Keymed", HKEX: 02162), today announced a collaboration to jointly discover and develop first-in-class siRNA therapeutics for Glomerulonephritis (also referred as severe kidney diseases). The collaborat...
2023-05-15 12:30
2505
Innovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma
ROCKVILLE, Md. and SUZHOU, China, May 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and...
2023-05-15 08:00
3665
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
SHANGHAI, May 12, 2023 /PRNewswire/ -- LaNova Medicines Ltd. ("LaNova Medicines") announced today it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C...
2023-05-12 23:30
4112
Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
GAITHERSBURG, Md., May 12, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health Sciences Authority (HSA) has granted extended interim authorization and the Ministry of Heal...
2023-05-12 21:01
5536
Crystal Formulation Services' GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion
SUZHOU, China, May 12, 2023 /PRNewswire/ -- Today, Crystal Pharmatech announced that the GMP manufacturing facility of their CDMO business unit – Crystal Formulation Services (CFS) has successfully passed a remote audit conducted by a US client. The audit, which lasted for four days, confirmed th...
2023-05-12 21:00
2288
CRM Trial Connect 2023: Minister of Health Malaysia, Dr. Zaliha Mustafa visits Taimei Technology's booth
SHANGHAI, May 12, 2023 /PRNewswire/ -- Taimei Technology, the digital platform for life science industry, attendedCRM Trial Connect 2023 held at the InterContinental Kuala Lumpur fromMay 11 to May 12, 2023. During the event, Dr. Zaliha Mustafa, Minister of Health Malaysia visited Taimei Technolog...
2023-05-12 19:36
4400
Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
JINAN, China, May 12, 2023 /PRNewswire/ -- On May 8, 2023, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (J Hematol Oncol. 2023May 8;16(1):50). This study is the...
2023-05-12 17:40
2162
Nefecon Included in the Reimbursement Drug List of "Beijing Puhui Health Insurance Program" as a First-in-Disease Therapy for IgA Nephropathy
SHANGHAI, May 12, 2023 /PRNewswire/ -- An imported version of Nefecon (budesonide) delayed release capsule has been added to the 2023 New Reimbursement Drug List of Specialized Medicines of the "Beijing Puhui Health Insurance Program." Nefecon is a first-in-disease treatment for adults with prim...
2023-05-12 07:40
4193
Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
SUZHOU, China, May 11, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatm...
2023-05-11 23:30
2566
Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
JINAN, China, May 11, 2023 /PRNewswire/ -- On May 8, 2023, the authoritative oncology journal, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (Title: First-in-hum...
2023-05-11 20:55
2385
PFIZER CALLS FOR MORE AWARENESS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) - A RARE, LIFE-THREATENING DISEASE
KUALA LUMPUR, Malaysia, May 11, 2023 /PRNewswire/ -- In an effort to encourage people to take care of their heart health, Pfizer Malaysia is calling for Malaysians to learn more about transthyretin amyloid cardiomyopathy (ATTR-CM), a rare, life-threatening disease. ATTR-CM is caused by unstable ...
2023-05-11 16:10
3173
Nippon Express Italia Obtains IATA CEIV Pharma Certification for Its Facility near Milan Malpensa Airport
TOKYO, May 11, 2023 /PRNewswire/ -- Nippon Express Italia S.p.A. (hereinafter "NX Italia"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association...
2023-05-11 14:00
2659
SHL Medical and MoonLake Immunotherapeutics collaborate to develop sonelokimab autoinjector
ZUG, Switerland, May 11, 2023 /PRNewswire/ -- SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inf...
2023-05-11 09:00
3778
Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
ROCKVILLIE, Md. and SUZHOU, China, May 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-05-11 08:45
4850
Fosun Pharma Participates in BEYOND Expo 2023 to Showcase Its Innovative R&D Achievements
MACAU, May 10, 2023 /PRNewswire/ -- From May 10 to 12, 2023, the 3rd BEYOND International Technology Innovation Expo — also known as BEYOND Expo 2023is being held at the Venetian Macau Convention and Exhibition Center. This year is the third consecutive year that Fosun Pharma (stock code: 600196....
2023-05-10 22:57
3057
Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma
* Marketing Authorization granted for Tibsovo® as the first and only approved IDH1 targeted therapyin Europe * IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma, difficult and hard-to-treat cancer PARIS, May 10, 2023 /PRNewswire/ -- Servier, a global pharmaceutical group...
2023-05-10 20:58
1955
Doceree forms an exclusive partnership with Hello Health Group to strengthen its global footprint; forays into 8 South East Asian markets
The partnership opens a first-of-its-kind service for Hello Health Group's
pharmaceutical clients,enabling them to target HCPs with precision and
efficiency
NEW DELHI, May 10, 2023 /PRNewswire/ -- Doceree
2023-05-10 11:00
3375
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy
ROCKVILLIE, Md. and SUZHOU, China, May 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and ...
2023-05-10 08:00
4107
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting
FLORENCE, Italy and NEW YORK, May 9, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of the Menarini Group, announced today that they will present new data related to ...
2023-05-09 22:57
3015
CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology
SINGAPORE, May 9, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (Nasdaq: GDTC) ("CytoMed" or the "Company"), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, today ...
2023-05-09 22:07
2583
Week's Top Stories
Most Reposted
2024 Malaysia E-Commerce Product Selection Expo Attracts International Delegations
[Picked up by 307 media titles]
2024-12-02 12:06
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 303 media titles]
2024-11-26 18:49ITAP 2024 sets the stage for a more connected advanced factory ecosystem with focus on AI, advanced robotics and sustainability
[Picked up by 298 media titles]
2024-11-28 17:24Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 296 media titles]
2024-11-26 13:00Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
[Picked up by 284 media titles]
2024-11-29 20:33
Most Read
Mentech at COP29: Showing the Eco-friendly Lifestyle with Technological Innovation
2024-11-29 20:33
7860
Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
2024-11-26 13:00
5180